Objective Bacillus cereus (B. cereus) septicemia is a cause of life-threatening infection in patients with hematologic diseases. However, preventing a fatal prognosis in patients with B. cereus infection has not yet been achieved due to insufficient clinical investigations. To discover more optimal treatment strategies, we analyzed B. cereus septicemia in patients with hematologic diseases. Methods At our institution, we observed 13 cases of B. cereus septicemia in 12 patients with hematologic diseases between January 2001 and September 2010. The susceptibility of B. cereus strains to antibiotics was also analyzed. Results Of 12 patients, four died of B. cereus septicemia. In this study, the delayed administration of appropriate antibiotics (starting >24 hours after presentation), the presence of liver dysfunction and evidence of central nervous system (CNS) involvement tended to result in a fatal prognosis. All of the bacterial strains were found to be susceptible to vancomycin and quinolones (such as ciprofloxacin and levofloxacin), whereas many strains were resistant to clindamycin (76.9%) and imipenem (30.8%). In seven of 10 patients, central venous (CV) catheter tips were removed and routinely cultured. Catheter tip cultures were positive for B. cereus in three of seven patients. Conclusion Although not specific to B. cereus bacteremia, patients who died of B. cereus tended to present with CNS symptoms and/or liver dysfunction. Our clinical data suggested that carbapenem and clindamycin are no longer appropriate choices for treating B. cereus. In addition, B. cereus septicemia was found to frequently originate from CV catheters. Constant attention must be paid to update assessments of antibiotic susceptibility and careful management must be applied to CV catheters in patients with hematologic diseases.
Introduction
Bacillus cereus is a gram-positive, spore-forming, rodshaped bacterium that is widely distributed in the environment. This pathogen is a common cause of food poisoning (1, 2) and may cause septicemia, surgical wound infection, pneumonia or meningitis in immunocompromised patients (3). Akiyama et al. reported the case of a patient with ported 12 cases and analyzed a total of 58 previously reported cases of B. cereus septicemia in patients with hematologic malignancies (5) . Their analysis indicated that acute leukemia, a neutrophil count of near 0/μL or the presence of central nervous system (CNS) symptoms during febrile episodes are associated with fatal prognoses.
Despite these previous case series, an optimal treatment strategy for B. cereus septicemia has not yet been established. In recent years, we have encountered several cases of B. cereus septicemia, four of which were fatal, in patients with hematological diseases at our institute. In the present study, we reviewed the data and clinical features of patients with B. cereus septicemia in a retrospective fashion and attempted to establish improved treatment strategies.
Materials and Methods

Patients
The medical records of inpatients with hematological diseases who produced positive blood cultures for B. cereus at Nihon University Itabashi Hospital between January 2001 and September 2010 were reviewed for this analysis. With regard to patients with septicemia, the charts were reviewed to obtain clinical information, including age, sex, underlying disease, insertion of a central venous (CV) catheter, neutrophil count at onset, prior chemotherapy, timing of use of appropriate antibiotics and prognosis. Time to death was calculated as the interval from the date of onset to the date of death. In addition, clinical signs during febrile events such as gastrointestinal (GI) or CNS symptoms were recorded. In addition, the presence or absence of liver dysfunction as shown by elevation of the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels after onset was determined according to the Common Terminology Criteria for Adverse Events ver. 3.0. This criteria was used because hepatic necrosis and/or hepatic infiltration of B. cereus have frequently been reported (5) . This retrospective analysis was approved by the institutional review board of the hospital.
Diagnostic criteria for B. cereus infection
During the treatment period, inpatients were given standard surveillance for infection, including monitoring of body temperature, clinical symptoms and C-reactive protein. Patients who were suspected to have infection underwent further diagnostic investigation. Two sets of blood samples, i.e. cultured for both aerobic and anaerobic bacteria, were routinely taken from all patients who developed high-grade fevers of over 38 . Identification of B. cereus was made on the basis of Gram staining and colony morphology. We defined a case of septicemia when at least two blood culture sets were positive for B. cereus or when at least one set turned positive with verification from a distant site (catheter tip, abscess, etc.). Febrile cases that did not satisfy the above criteria were excluded from this analysis.
Culture conditions and assessment of susceptibility
Prior to susceptibility testing, bacterial samples were grown on trypticase soy agar II with 5% sheep red blood cells (TSAII) (Becton Dickinson, San Jose, CA, USA). All plates were incubated at 37 in ambient air before testing. Anti-microbial disk susceptibility tests were also performed using the Sensi-Disc system (Becton Dickinson). Standard breakpoints of minimum inhibitory concentration (MIC) with susceptibility were set according to Clinical and Laboratory Standards Institute (CLSI) M100 S19 generation guidelines as follows: penicillin-G (PCG) ! 2 μg/mL, ampicillin (ABPC) ! 8 μg/mL, cefotaxime (CTX) ! 8 μg/mL, imipenem (IPM) ! 4 μg/mL, ciprofloxacin (CPFX) ! 2 μg/ mL, levofloxacin (LVFX) ! 2 μg/mL, clindamycin (CLDM) ! 0.5 μg/mL, vancomycin (VCM) ! 4 μg/mL, clarithromycin (CAM) ! 0.25 μg/mL and gentamicin (GM) ! 4 μg/mL (http://www.clsi.org/).
Results
Characteristics of patients with B. cereus septicemia
The demographic data of the patients diagnosed with B. cereus septicemia are shown in Tables 1, 2 . Within the outlined observation period, a total of 45 patients had at least one positive blood culture for B. cereus at our institute. Of these, 13 cases met the criteria for B. cereus septicemia, including 12 cases with two sets of positive blood cultures and one case with a single set of positive cultures in addition to a positive CV catheter tip culture (patient 7). CV catheter tips were removed from seven of 10 patients (patients 1, 3, 5, 7, 9, 11 and 13) with CV catheters and routinely cultured. In three of seven patients, the catheter tip cultures were positive for B. cereus (patients 3, 5 and 7). One patient contracted two separate B. cereus infections during CV catheter removal after achieving full recovery from septicemia. Each instance is reported separately (patients 3 and 4).
The patients included in this study ranged in age from 18 to 80 years (median 60 years). The population was largely female (66.7%) and most patients had CV catheters (76.9%). Neutrophil counts ranged from 0 to 4,500/μL (mean 1,156/ μL) at onset with a minority of patients having GI (38.5%) or CNS symptoms (15.4%). With respect to underlying hematologic disorders, there were seven cases of acute myeloid leukemia (AML) and one case each of acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), myelodysplastic syndrome (MDS) and aplastic anemia (AA). All but one patient with AML, ALL, or NHL had received intensive chemotherapy. One patient had undergone allogeneic hematopoietic stem cell transplantation and developed concomitant acute graft-versus-host disease. Of the 13 patients with B. cereus septicemia, four died of infection and nine fully recovered, thus resulting in a 31% mortality rate. The causes of death were clinically considered to be septic shock (patient 12), multiple organ failure caused by disseminated intravascular coagulation (patients 10, 11 and 13) and/or complications of CNS injury (patients 11 and 13). Two patients experienced CNS symptoms of convulsions and coma, and one (patient 11) developed central diabetes insipidus. Computed tomography (CT) scanning was performed in patients with CNS symptoms that developed after onset; however, no abnormal findings were revealed. Additionally, either abdominal CT scanning or ultrasonography was performed in patients with grade ! 3 liver dysfunction; however, this did not lead to a diagnosis of the cause of the liver dysfunction in any case. Of the 32 patients who did not satisfy the above criteria, nine had NHL, eight had AML, three had ALL, three had MDS, three had multiple myeloma (MM), two had anti-phospholipid syndrome (APS), two had CML, one had acute T-cell leukemia (ATL) and one had chronic lymphocytic leukemia (CLL). In this population, 25 (71.4%) patients had severe neutropenia (less than 500/μL of neutrophils) at onset that developed into febrile neutropenia after chemotherapy. The age distribution of these patients was similar to that of the patients who met the criteria (range 15-76, median 54.5 years). In contrast to the high mortality rate observed in patients diagnosed with B. cereus septicemia, only one of the 32 patients who did not satisfy the above criteria died of infectious complications. The mortality case had NHL without neutropenia at onset and a time to death of eight days after onset.
Assessment of prognostic factors
The results of the analysis are shown in Table 3 . In this study, the presence of CNS symptoms was associated with 18% ) and delayed onset (>24 hours) of appropriate antibiotic coverage for B. cereus. Patients whose antibiotic coverage was delayed exhibited an increase in mortality compared to those who received appropriate antibiotics immediately (50% vs. 0% mortality). "Appropriate treatment" was defined by the results of antibiotic susceptibility testing after speciation of B. cereus. All five patients who received immediate, appropriate antibiotic treatment for B. cereus fully recovered from septicemia, whereas four of the remaining eight patients who did not receive appropriate antibiotics within 24 hours died of B. cereus septicemia. In addition, the presence of severe AST or ALT elevation (grade " 3), thus suggesting that the involvement of B. cereus colonies was associated with mortality (100% vs. 18%). Age " 60 years, sex, the presence of a CV catheter, a neutrophil count ! 500/μL, a diagnosis of leukemia (vs. other hematologic disorders) and the presence of GI symptoms were not associated with adverse patient outcomes.
Antibiotic susceptibility
As shown in Fig. 1 , the antibiotics used to treat patients in this study included PCG, ABPC, CTX, IPM, CPFX, LVFX, CLDM, VCM, CAM and GM. In vitro results showed that all B. cereus samples tested were resistant to PCG (0/13, 0% sensitive), ABPC (0/5, 0% sensitive) and CTX (0/5, 0% sensitive). In contrast, 100% susceptibility was observed to quinolones, such as CPFX (10/10, 100% sensitive) and LVFX (5/5, 100% sensitive), as well as VCM and GM (13/13, 100% and 3/3, 100% sensitive, respectively).
Non-sensitive (intermediate + resistant) strains were tested for susceptibility to CLDM (3/13, 23.1% sensitive) and IPM (9/13, 69.2% sensitive). The IPM results were surprising, as sensitivity to this carbapenem-family antibiotic, previously considered to be effective for B. cereus infection, was not adequate. To complete an analysis with larger numbers, we collected and tested the susceptibility of 37 B. cereus samples, including single positive samples from blood cultures, isolated from patients with hematologic diseases. The results are shown in Fig. 2 . The results were very similar to those of Fig. 1 .
Discussion
In this series, we report 13 cases of B. cereus septicemia occurring in patients with hematological diseases and discuss the associated high mortality rate in accordance with the results of previous reports (4, 5) . In the department of hematology at our hospital, chemotherapy is provided an estimated 100 to 200 times per year, including 40 to 60 courses of intensive chemotherapy for leukemia patients and 50 to 90 courses of chemotherapy for patients with lymphomas requiring granulocyte colony-stimulating factor support. The incidence of intensive chemotherapy is estimated to be 1-2% in patients with leukemia and is lowest in patients with lymphoma. Surveillance of AML patients under intensive chemotherapy in the Japanese population showed that the incidence of B. cereus septicemia accounts for 2% of all cases of bacteremia or fungemia (6) . Although the overall incidence of B. cereus septicemia is low, septicemia should be considered a serious complication given its high mortality rate. Therefore, expedited diagnosis, treatment and prophylactic strategies are important.
In our study, B. cereus septicemia was more likely to occur in patients receiving chemotherapy for leukemia. In patients fitting this clinical profile, even a single positive culture for B. cereus should not be regarded as contamination. Further additional blood cultures are therefore required. For patients with a positive culture without any other originated infectious lesions, any CV catheters may be considered to be causes of septicemia. In this study, catheter tip cultures were positive in three of seven cases. These results suggest that B. cereus septicemia may frequently originate from CV catheters and spread to the bloodstream. This finding is in accordance with those of recent reports, suggesting that the Bacillus species causes nosocomial bacteremia via catheter infection (7) (8) (9) . Importantly, the Bacillus species can form biofilms, and biofilm-forming strains can potentially cause nosocomial bacteremia by catheter infection (10) (11) (12) . Antibiotic therapy typically reverses the symptoms caused by planktonic organisms released from biofilms; however, antibiotics are unable to penetrate the film to affect the organisms within. For this reason, patients with biofilm infections typically show recurring symptoms following cycles of antibiotic therapy until the sessile population is removed from the body (13) . Therefore, the removal of any infected CV catheter is important for both diagnosis and treatment. In our series, all three patients whose B. cereus infections were detected via catheter tip culture, and whose CV catheters were removed within one day after the onset of symptoms, fully recovered from septicemia. Our analysis did not identify the insertion of a CV catheter as a prognostic factor, in contrast to the report by Inoue and colleagues (5), thus suggesting that early removal might contribute to favorable prognoses.
In the current study, most of the fatal cases progressed rapidly, as described in a previous report (4) . The rapid declines underscore the significance of pre-emptive antibiotic therapy for B. cereus infection and the need for a low threshold for treatment. Despite a relatively small number of fatalities reported, we could surmise that immediate, appropriate antibiotic treatment may significantly improve patient outcomes. Therefore, appropriate antibiotics should be given as soon as B. cereus is detected in any blood culture sample obtained from a patient with hematological disease, especially in patients receiving intensive chemotherapy. Hence, the clinical question is: What agents are most effective?
The optimal antibiotics for treating B. cereus are generally considered to be VCM, quinolones, CLDM or carbapenems. As shown in Fig. 1, all isolates of B. cereus in our study were susceptible to VCM and quinolones. However, partial resistance to CLDM and carbapenem was detected, similar to the results of previous basic research and a case report (14, 15) . Our clinical data suggest that carbapenem and CLDM are no longer appropriate choices for treating B. cereus, in accordance with findings that susceptibility to carbapenems has fallen in the S20 generation (http://www. clsi.org). Therefore, it is speculated that the incidence of B. cereus infections resistant to carbapenem will increase in the future.
Clinically, CNS symptoms were highly correlated to mortality. A pooled analysis of the 13 cases reported here and a prior report by Inoue et al. demonstrate statistical significance for survival in the presence or absence of CNS symptoms (5) . That is, the presence of CNS symptoms significantly predicts a poorer clinical outcome with a tremendously high mortality rate. It has been postulated that CNS symptoms result from severe central nervous complications such as meningitis, brain abscess or cerebral bleeding (5, 16) . Unfortunately, a definitive etiology for CNS symptoms could not be identified in our patient population because of insufficient examination due to rapid downhill courses and/or uncontrolled convulsions. A literature search revealed a single case of B. cereus septicemia with a brain abscess in which the patient required surgical drainage to achieve a cure (17) . It should be noted that although intravenous injection of VCM is effective for B. cereus septicemia, it is less effective for encephalomeningitis due to low achievable concentrations in cerebral spinal fluid (16) . These previous reports indicate that patients with CNS symptoms should be treated more aggressively with measures such as surgical drainage for brain abscesses or the intrathecal administration of VCM for encephalomeningitis whenever possible.
According to the data analysis in our study, an important trend surfaced regarding overall infection rates with B. cereus. The use of prophylactic administration of antibiotics in patients with severe neutropenia was decided by physicians in our institution. Since 2005, prophylaxis with quinolones has been frequently administered because its efficacy was shown in a large-scale, prospective study at that time (18) . Overall, almost half of all patients with acute leukemia receiving intensive chemotherapy received prophylactic administration of quinolones, whereas prophylactic treatment was rarely administered to those with lymphoma. Interestingly, no patient with leukemia who received prophylaxis with quinolones developed B. cereus septicemia. These results are not statistically proven; however, they suggest that antibacterial prophylaxis with quinolones may be beneficial for leukemia patients receiving intensive chemotherapy in order to prevent B. cereus septicemia. A detailed study of the prophylactic efficacy of quinolones is currently underway.
Overall, we confirmed the following diagnostic, treatment and prophylactic strategy for treating B. cereus septicemia in patients with hematologic disease:
1) The presence of B. cereus in blood cultures should not be regarded as contamination in patients receiving intensive chemotherapy for leukemia (4-6).
2) If one set of blood cultures is positive for B. cereus, further investigation is required. CV catheters should be taken into consideration as a potential origin of B. cereus septicemia (7-9).
3) Pre-emptive therapy is recommended if B. cereus septicemia is suspected. VCM or quinolones, but not carbapenems or CLDM, should be chosen to treat B. cereus septicemia (14, 15) . 4) If the patient has CNS symptoms, aggressive treatment options in addition to intravenous administration of antibiotics should be considered immediately (16, 17) . 5) Prophylaxis with quinolones might reduce the incidence of B. cereus infection.
The relative importance of early diagnosis, drug-resistance and efficacy of prophylaxis treatment for B. cereus infection remains to be elucidated, while the prevention of contamination through indwelling catheters or the nosocomial environment has been established (19) . There are currently no established guidelines for the overall management of this condition. To address these issues, further, larger, well-designed prospective studies are required.
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